No NFO data available for this page.
3 Year return
16.24%Investment Details
Calculate Returns
Based on past performance of this fund
Risk Involved
Your principal will be at
Very High Risk
Asset Under Management
₹2667.21 Cr.
Expense Ratio
0.95% (inclusive of GST)
Exit Load
0.50% - If redeemed/switched out wihin 15 days from the date of allotment. Nil - If redeemed/switched out after 15 days from the date of allotment.
Tax Implications
Withdrawal within 1 year
Exit load + 15% tax on gains
Withdrawal after 1 year
10% tax on gains over ₹1 Lakh per financial year
Fund Holdings
Other Holdings | % of Asset |
---|---|
Mankind Pharma | 4.96 % |
Aether Industri. | 4.37 % |
Jupiter Life Lin | 4.01 % |
Lupin | 3.95 % |
Aurobindo Pharma | 3.89 % |
Krishna Institu. | 3.81 % |
Global Health | 3.65 % |
Rainbow Child. | 3.61 % |
Abbott India | 3.57 % |
Gland Pharma | 3.46 % |
Fortis Health. | 3.29 % |
Torrent Pharma. | 2.97 % |
J B Chem & Pharm | 2.68 % |
Aster DM Health. | 2.35 % |
Zydus Lifesci. | 2 % |
Alkem Lab | 1.99 % |
Laurus Labs | 1.52 % |
TREPS | 1.52 % |
Gufic BioScience | 1.23 % |
Dr Lal Pathlabs | 1.11 % |
Vijaya Diagnost. | 0.52 % |
Net CA & Others | 0.5 % |
Shreno Ltd | 0.25 % |
SBI Mutual Fund Managers
TD
Tanmaya Desai
Fund Manager since Jun 2011
Fund House Details
SBI Mutual Fund Asset management company
Peer Comparison
Comparison with other similar funds
Funds
|
3 Y Returns
|
ARQ Rating
|
---|---|---|
Invesco India PSU Equity Fund Direct Plan IDCW (Payout / Payout) |
42.14% |
0 |
Quant Infrastructure Fund IDCW Direct Plan Payout |
38.55% |
0 |
Invesco India Infrastructure Fund Direct Plan IDCW (Payout / Payout) |
37.43% |
0 |
Schemes by SBI Mutual Fund
List of mutual fund schemes by AMC
Hybrid . Arbitrage Fund
SBI Arbitrage Opportunities Fund Direct Plan Gr
Hybrid . Arbitrage Fund
SBI Arbitrage Opportunities Fund Direct Plan IDCW Payout
Hybrid . Arbitrage Fund
SBI Arbitrage Opportunities Fund Direct Plan IDCW Reinvestment
Equity . Sectoral / Thematic
SBI Automotive Opportunities Fund Direct Plan Growth
Equity . Sectoral / Thematic
SBI Automotive Opportunities Fund Direct Plan IDCW Payout
About SBI Healthcare Opportunities Fund Direct Plan Growth
SBI Healthcare Opportunities Fund Direct Plan Growth was previously known as the SBI Pharma Fund that is offered by the SBI Mutual Fund House. It is an open-ended equity scheme. The fund predominantly invests in the healthcare sector and is categorised as a sectoral/thematic scheme. The fund is benchmarked against the S&P BSE Healthcare Index.
Investment Objective of the Scheme
By investing in a diverse portfolio of equities and equity-related instruments in the healthcare sector, the SBI Healthcare Opportunities Fund Direct Plan Growth scheme aims to give its investors the chance of long-term financial growth and appreciation. The fund identifies companies in the healthcare sector using a bottom-up approach to stock selection. The fund invests in pharmaceuticals, hospitals, medical equipment, healthcare service providers, and biotechnology companies.
Key Features of The Fund
5-year return | 26.31% |
Expense Ratio | 0.95% |
Fund Manager | Tanmaya Desai |
Fund Size | ₹2667.21 Cr |
Risk Profile | Very High |
Is This Scheme Right for Me?
The SBI Healthcare Opportunities Fund Direct Plan Growth is appropriate for long-term capital appreciation investors. You would have the option to choose between SIP and Lump Sum while making an investment in this scheme. This plan would also appeal to investors interested in equity investments in healthcare-related stocks. However, it is important to note that the scheme comes with a very high risk. Nonetheless, before you make any investment decisions, you must see that your financial goals and future plans are aligned with your investment.
AMC Contact Details
Name | SBI Mutual Fund |
Launch Date | June 1987 |
Addresss | 9th Floor, Crescenzo, C-38 & 39, G Block, Bandra-Kurla Complex, Mumbai, Maharashtra, India - 400 051 |
Contact | 1800 209 33331800 425 5425 |
customer.delight@sbimf.com | |
Website | https://www.sbimf.com/ |
Disclaimer: Mutual funds are subject to market risk. Read all scheme-related documents carefully to make informed-decision.